Prescribe to Prevent: Overdose Prevention and Naloxone Rescue Kits for Prescribers and Pharmacists

Jamie K. Lim, BSc, Jeffrey P. Bratberg, PharmD, Corey S. Davis, JD, MSPH, Traci C. Green, PhD, MSc, and Alexander Y. Walley, MD, MSc

In March of 2015, the United States Department of Health and Human Services identified 3 priority areas to reduce opioid use disorders and overdose, which are as follows: opioid-prescribing practices; expanded use and distribution of naloxone; and expansion of medication-assisted treatment. In this narrative review of overdose prevention and the role of prescribers and pharmacists in distributing naloxone, we address these priority areas and present a clinical scenario within the review involving a pharmacist, a patient with chronic pain and anxiety, and a primary care physician. We also discuss current laws related to naloxone prescribing and dispensing. This review was adapted from the Prescribe to Prevent online continuing medical education module created for prescribers and pharmacists (http://www.opioidprescribing.com/naloxone_module_1-landing).

Key Words: pain, prescription drug abuse, prevention, public health, substance abuse

(J Addict Med 2016;10: 300–308)

Clinical scenario: Upon filling a prescription for oxycodeone, a pharmacist reviews the patient’s other medications: “In the Prescription Monitoring Program, I see that you’re also being prescribed clonazepam by another physician. I wanted to make sure that you understand that combining pain medications, like oxycodone, and anxiety medications, like clonazepam, can increase your risk of drowsiness, sedation, and even overdose.” The patient replies that she has been taking these medications for a long time and is not concerned. “I’m glad to hear that you’re aware of the risks,” the pharmacist says, “With your permission, I’m going to contact your prescribers, so we can monitor your risk and keep you safe.”

EPIDEMIOLOGY

Drug overdose, driven largely by use of prescription opioids and heroin, is now the leading cause of accidental injury death in the United States, surpassing those caused by motor vehicle crashes (U.S. Food and Drug Administration, 2014; U.S. Centers for Disease Control and Prevention, 2015a, 2015b). From 2005 to 2013, annual opioid-related overdose deaths almost doubled, from 12,937 to 24,492 (Jones et al., 2013; Wheeler et al., 2015). The economic costs to society have been projected to surpass $20 billion every year (Inocencio et al., 2013). This overdose crisis has been linked to the availability and potency of prescribed opioids (Okie, 2010; Modarai et al., 2013; Chen et al., 2014; Dart et al., 2015). Whereas 71% of those who are at risk to misuse pain relievers report obtaining the medications from family and friends, 79% of those family and friends report being prescribed those medicines by their doctor (Substance Abuse and Mental Health Services Administration, 2011). Both qualitative and epidemiologic studies have also demonstrated that heroin addiction is often preceded by prescription opioid misuse (Jones, 2013; Dasgupta et al., 2014; Mars et al., 2014; LaRochelle et al., 2015). Furthermore, fentanyl-related overdose fatalities have increased, involving fentanyl manufactured and distributed illicitly as part of the street drug market (U.S. Centers for Disease Control and Prevention, 2015c).

How Does an Opioid Overdose Occur?

Opioid receptors are found throughout the nervous system, including the sections of the brainstem that control breathing. Stimulation of the receptors by opioids can cause euphoria, pain relief, sedation, and decreased respiration. High doses of opioids cause reduced sensitivity to oxygen and carbon dioxide levels, reducing respiratory drive and
allowing tidal volume and respiratory rate to decrease. The resulting hypoxia can cause a loss of consciousness, and eventually, death. Signs of an overdose include decreases in respiratory rate, abnormal breathing sounds (snoring, gurgling, choking, etc.), decreased consciousness, miosis, and a blue/gray tinge of the skin, especially the lips and nail beds (White and Irvine, 1999).

**PREVENTION**

**What are Common Risks for Opioid Overdose?**

Medical providers and pharmacists should understand, explain to patients, and take actions to reduce overdose risk. The following should be considered when assessing a patient’s risk.

First, **previous nonfatal overdose** is associated with future overdose (Kinner et al., 2012). Second, **higher opioid doses**, such as daily doses higher than 50 morphine milli-equivalents (Dunn et al., 2010), and **changes in dose or formulations** increase overdose risk; people who use heroin are thus frequently at risk due to unpredictable changes in substance purity from, for example, adulteration with fentanyl (Rudd et al., 2015). Third, **polypharmacy and mixing substances** contribute to overdose risk, as opioid overdoses commonly involve other substances (Jones et al., 2013, 2014). Psychoactive medications of particular concern include barbiturates, stimulants, and benzodiazepines (Jann et al., 2014; Zedler et al., 2014; Jones and McAninch, 2015). Other medications that can have synergistically central nervous system depressive effects include clonidine (Beuger et al., 1998), promethazine (Shapiro et al., 2013; Lynch et al., 2015), and gabapentin (Smith et al., 2015). Fourth, **socially isolated individuals** who use prescription opioids or heroin alone have little chance of being rescued. Isolation is also associated with depression, which is itself associated with overdose (Cacioppo et al., 2006; Madadi et al., 2013). Fifth, **chronic medical illnesses** involving organs, such as the lung, liver, kidney, and brain, primarily responsible for metabolizing substances and respiration, can compromise the body’s ability to handle opioids (Zedler et al., 2014). Sixth, **periods of abstinence**, such as periods of incarceration, hospitalization, and medical detoxification, cause reduced opioid tolerance and thus increased overdose risk. Accordingly, providers should educate and monitor patients restarting opioids or at risk of relapse (Wolff, 2002; Strang et al., 2003; Moller et al., 2010).

**Assessing a Patient’s Overdose Risk**

Prescribers should assess overdose risk as part of a patient’s history by the following means: reviewing medications and checking the Prescription Monitoring Program (PMP); reviewing medical and social history for above-mentioned risk factors; obtaining a focused substance use history; and obtaining an overdose history. The overdose history should determine if the patient has personally experienced an overdose (“Have you ever overdosed? What strategies do you use to prevent yourself from overdosing?”), witnessed an overdose (“Have you witnessed an overdose?”), or received training to prevent, recognize, and/or respond to one (“How would you respond to an overdose?”). Understanding the patient’s experience and knowledge should guide the education provided.

Pharmacists should review medications, optimize medication safety, and provide patient education. This includes checking the PMP for psychoactive or sedating medications, addressing potential drug–drug interactions, ensuring that prescribers are aware of the patient’s prescriptions, confirming understanding of the risks of opioids, providing overdose education, and filling naloxone prescriptions, or, when permitted, directly providing naloxone to the patient.

The pharmacist calls the primary care doctor: “I saw your patient has prescriptions for both oxycodone and clonazepam and informed her of the risks of combining these medications.” The doctor replies, “I was not aware of the clonazepam prescription. Who is the prescriber?” The pharmacist offers the other prescriber’s name, which the doctor recognizes. “That makes sense. He’s a psychiatrist that I refer my patients to. I’ll discuss the risks with the patient at our appointment coming up.”

**Strategies to Address Overdose**

There are several existing strategies that address the Department of Health and Human Services’ priority areas of improving opioid-prescribing safety and access to medication-assisted treatment (U.S. Department of Health and Human Services, 2015). Safe opioid-prescribing education has been supported by the Federal Drug Administration (FDA) and is mandated in some states like Massachusetts for prescribers to be relicensed (U.S. Food and Drug Administration, 2013). PMPs allow for prescribers and pharmacists to monitor what controlled substances a patient is filling at the pharmacy (Paulozzi et al., 2011; Davis et al., 2014a). Evidence of their effectiveness as overdose prevention tools is still mixed (Li et al., 2014; Green et al., 2015a). Prescription drug disposal in many communities occurs at kiosks, often hosted at local police stations and other locations, with support from Drug Enforcement Administration (DEA) which holds nationwide “take-back” events (Gray and Hagemeier, 2012; U.S. Drug Enforcement Administration, 2015). The DEA now also permits manufacturers, distributors, treatment programs, pharmacies, and healthcare facilities to become authorized collectors of prescription medications (U.S. Drug Enforcement Administration, 2014). Finally, medication for opioid use disorders, specifically methadone, buprenorphine, and naltrexone, is supported by evidence for increased abstinence and decreased opioid use (Schwartz et al., 2006; Mattick et al., 2009; Krupitsky et al., 2011; Mattick et al., 2014). Methadone and buprenorphine treatment is also associated with decreased criminal activity (Bell et al., 1997; Dolan et al., 2005; Lobmann and Verthein, 2009; Bukten et al., 2012; Soyka et al., 2012), improved birth outcomes (Johnson et al., 2001; Fajemirokun-Okudeyi et al., 2006; Meyer et al., 2012), and less overdose (Langendam et al., 2001; Clausen et al., 2009; Schwartz et al., 2013).

“Your pharmacist contacted me about the risks of taking both clonazepam and oxycodone,” the doctor informs the patient at their appointment. The patient does not understand the concern. The doctor explains that these medications have interactions that increase the chance of drowsiness and overdose, especially if she uses substances.
like alcohol or other drugs. “Do you ever feel drowsy or sedated from your medications?” The patient acknowledges one event when she took an extra oxycodone and clonazepam, after which her husband had trouble waking her up. The patient says that she now never takes anything more than what she is prescribed, and knows to call the doctor if she is struggling with pain, and her psychiatrist if she is struggling with her anxiety.

When the doctor asks how she stores her medication, she reports that she has started hiding pills from her son, “He got his wisdom teeth out and was given pain medication, and then he sprained his ankle and was given even more. I’m worried he has a drug problem and has switched over to heroin.” According to the patient, on previous occasions after leaving treatment, he immediately relapsed, and she is now worried about him overdosing. The doctor reiterates the risk of overdose following a period of abstinence, and asks if she has a plan if her son should overdose. The patient says that she knows to call an ambulance and start rescue breathing, “But what else can I do?”

**RESPONSE**

### What are Naloxone Rescue Kits?

Naloxone is an opioid antagonist that displaces opioids from brain receptors and restores breathing and consciousness. Naloxone is a prescription medication, but not a controlled substance. It usually takes 2 to 5 minutes to take effect and wears off after 30 to 90 minutes, so patients on long-acting opioids like methadone and extended-release oxycodone may have recurrent reduced respirations and overdose (Chamberlain and Klein, 1994). Overdose responders should be encouraged to stay with the person overdosing after administration of naloxone. In cases of polysubstance or high potency fentanyl-related overdose, standard doses of naloxone may be insufficient, and thus rescue breathing and help from the emergency medical providers may be necessary to reverse the overdose. Administering naloxone may precipitate withdrawal symptoms in the victim.

There are multiple reasons to equip people in the community with a naloxone rescue kit. First, most opioid users do not use alone, and so have people around them that can intervene should an overdose occur (Baca and Grant, 2007; Powis et al., 1999). Second, risk factors for overdose have been identified, as discussed above. Third, the extent of hypoxic brain injury is time-dependent, so the sooner hypoxia is reversed, the better (Michiels, 2004). Fourth, bystanders can be trained to recognize and respond effectively to overdoses with naloxone (Green et al., 2008; Clark et al., 2014). Finally, fear of being arrested sometimes discourages bystanders from calling for medical assistance, and thus makes naloxone an important tool for people hesitant to call for help (Davis et al., 2013).

Naloxone rescue kits have been endorsed by numerous organizations, including the American Medical Association (American Medical Association, 2015), American Society of Addiction Medicine (American Society of Addiction Medicine, 2014), American Pharmacists Association (American Pharmacists Association, 2014), Substance Abuse and Mental Health Services Administration (Substance Abuse and Mental Health Services Administration, 2014), World Health Organization (World Health Organization, 2014), and United Nations Office on Drugs and Crime (United Nations Office on Drugs and Crime, 2014). In 2015, the American Heart Association published guidelines on opioid overdose response with naloxone in an update to their guidelines for cardiopulmonary resuscitation and emergency cardiovascular care (Lavonas et al., 2015, Figure 1).

### What Evidence Exists to Support Overdose Prevention Education and Naloxone Rescue Kits?

Overdose education and naloxone distribution programs have existed since the late 1990s as community-based initiatives based out of harm-reduction programs (Maxwell et al., 2006; Sporer and Kral, 2007; Wheeler et al., 2012). Between 1996 and 2014, community organizations reported providing naloxone rescue kits to 152,283 laypersons and received reports of 26,463 overdose reversals (Wheeler et al., 2015).

Studies have shown feasibility of naloxone rescue kits in several different populations (Piper et al., 2008; Doe-Simkins et al., 2009; Enteen et al., 2010; Bennett et al., 2011; Walley et al., 2013a). Nonmedical bystanders can be effectively trained to respond to overdose (Green et al., 2008; Tobin et al., 2009; Wagner et al., 2010). Some have expressed concern that naloxone availability would result in increased opioid use, but this has not been observed. Drug treatment rates have either stayed constant or increased (Seal et al., 2005; Doe-Simkins et al., 2014). In several communities in which programs were implemented, overdose rates have decreased (Maxwell et al., 2006). In Massachusetts, where there was heterogeneous rollout of overdose prevention programs, communities with naloxone distributed to 1 to 100 people per 100,000 population saw opioid overdose death rates decrease by 27%, whereas in communities with naloxone distributed to over 100 people per 100,000 population, opioid overdose death rates declined by 46% (Walley et al., 2013b). In a 2013 study, a best-case scenario determined a cost of $438 per quality-adjusted life year (QALY) gained, whereas in the worst-case scenario, the cost was $14,000 per QALY gained (Coffin and Sullivan, 2013).

### Talking with Patients About Overdose Prevention and Response with Naloxone

Messages that providers can convey to patients:
- Only take opioids prescribed to you and as directed;
- If you are worried about your use of opioids, you can talk to me about it;
- If you are not taking opioids safely, I can help you find treatment;
- Make sure your prescribers and pharmacist are aware of all of your medications;
- Don’t mix opioids with other drugs or alcohol;
- Store medication in a safe and secure place, and dispose of unused medication;
- Abstinence can change tolerance, so if you stop taking opioids, a lower dose may be needed upon restart;
- Teach friends and family how to respond to an overdose, including how to use naloxone and where you store it;
- Know how to recognize and respond to an overdose when you witness one.
The doctor provides guidance for the patient and her son. “First, I’d like to monitor your medications more closely. I’m going to call your psychiatrist to discuss whether we should adjust your medications to something safer. I also recommend that you use a lock box, which you can get at the pharmacy, to secure your medications.” The doctor then devises a plan for her son. “Ask him to consider a treatment program that includes a medication for opioid addiction, like methadone or buprenorphine—here is a card to contact the treatment hotline. Lastly, for both you and your son, I’m going to prescribe a naloxone rescue kit. The kit includes a medication called naloxone, and comes with instructions on how to recognize and respond to an overdose.”

**FIGURE 1.** American Heart Association Opioid-Associated Life-Threatening Emergency (Adult) Algorithm. Reprinted with permission. Circulation. 2015;132:S501-S518. © 2015 American Heart Association, Inc. (http://circ.ahajournals.org/content/132/18_suppl_2/S501.long).

### Naloxone Rescue Kits at the Pharmacy: Prescribing, Stocking, Filling, and Billing

Prescribing naloxone rescue kits should be a collaborative effort between prescribers and pharmacists. Both have the duty to recognize and mitigate overdose risk.

Most major wholesalers carry naloxone formulations (Table 1). Outside of the inpatient setting, the most common methods of naloxone administration are intranasal and intramuscular. Evzio is an intramuscular formulation of naloxone in the form of an auto-injector (Beletsky, 2015).

To maintain its shelf life of 12 to 18 months, the product should only be drawn (for the intramuscular injection) or screwed (for the intranasal spray) into the syringe immediately before use. To maintain the shelf life, store at room temperature and protect from moisture and direct sunlight.
temperature, avoid environments with fluctuating extreme temperatures like inside unattended automobiles, and away from direct light (International Medications Systems Limited, 2015). Previously, the only option for intranasal naloxone was with the use of the intramuscular formulation with a luer-lock mucosal atomizer device (MAD), which must be stocked separately and does not have a national drug code. However, in November of 2015, the FDA approved a nasal naloxone spray, which requires no assembly (U.S. Food and Drug Administration, 2015). It is important to consider the patient’s individual preferences and needs when choosing between naloxone formulations.

A growing number of public and private insurers are covering naloxone formulations. Pharmacists can determine coverage and prior authorization requirements. The cost of naloxone varies by formulation and distributor, but is around $40 to $150 for an intranasal regimen—less for the intramuscular regimen, more for the auto-injector—which may place them out of reach for many uninsured patients (Massachusetts Department of Public Health, 2015). Kaleo, the manufacturer of the auto-injector (Evzio), has a patient assistance program that limits the out-of-pocket cost for eligible patients (Evzio, 2015). The MAD has an out-of-pocket cost of around $5 each.

Three models exist for accessing naloxone rescue kits through a pharmacy (Green et al., 2015b). First, a prescriber can write a prescription for naloxone and the patient can fill it at the pharmacy. There, pharmacists can determine if naloxone is covered by the patient’s insurance. Pharmacy staff should demonstrate the assembly and use of naloxone, and also provide further information on how to prevent, recognize, and respond to overdoses. Second, prescribers can write a prescription and, if permitted by state law, dispense the naloxone onsite. Third, pharmacies can provide naloxone directly to the patient via a pharmacist prescriber, or under a standing order, protocol, or collaborative practice agreement (CPA), explained in more detail below. In states that do not permit standing orders, protocols, or CPAs, pharmacists can contact the prescriber to have him or her call in or electronically send a prescription.

Variability exists across the country regarding availability and regulation of naloxone. Providers are encouraged to identify pharmacies in their areas that stock naloxone, and be aware of their state-specific laws surrounding naloxone prescribing.

The Legal Environment for Naloxone Prescribing and Dispensing

The legal environment for naloxone prescribing is in general no different than that for any other prescription medication. Prescribers must ensure that prescriptions are

---

**TABLE 1. Naloxone Formulations and Features**

| Injectable (and Nasal) | Intranasal Branded | Injectable Generic | Auto-injector Branded |
|------------------------|--------------------|-------------------|------------------------|
| FDA approval           | X (for IV, IM, SC) | X                 | X                      |
| Layperson experience   | X                  | X                 | X                      |
| Fragile; requires assembly | X                     | X                     |
| Can titrate dose       | X                  | X                 | X                      |
| Strength               | 1 mg/mL            | 4 mg/0.1 mL       | 0.4 mg/mL or 4 mg/10 mL | 0.4 mg/0.4 mL |
| Cost per kit           | $5                 | $5                | $                      | $55         |
| Rx and quantity        | #2, 2 mL Luer-Jet Luer-Lock needleless syringe plus #2 mucosal atomizer devices (MAD-300) | #1 two-pack of two 4-mg/0.1 mL intranasal devices | #2 single-use 1-mL vials or #1 10-mL multidose flip-top vial PLUS #2 5 mL syringe with 23 to 25 gauge 1-1.5 inch IM needles | #1 two-pack of two 0.4 mg/0.4 mL prefilled auto-injector devices |
| Sig. (for suspected opioid overdose) | Spray 1 mL (1/2 of syringe) into each nostril. Repeat after 2 to 3 minutes if no or minimal response | Spray 0.1 mL into one nostril. Repeat with second device into other nostril after 2 to 3 minutes if no or minimal response | Inject 1 mL in shoulder or thigh. Repeat after 2 to 3 minutes if no or minimal response | Inject into outer thigh as directed by English voice-prompt system. Place black side firmly on outer thigh and depress and hold for 5 seconds. Repeat with second device in 2 to 3 minutes if no or minimal response |

Some portions developed with funding from NIDA R01 DA034634.
issue in good faith, in the usual course of professional practice, and for a legitimate medical purpose (Aboud, 2010). The prescription of naloxone for a patient at risk of overdose satisfies all 3 criteria (Burris et al., 2009).

Whereas intranasal use with a MAD is technically considered an off-label use of the intramuscular formulation, prescription of the medication for intranasal administration does not change liability risk. Depending on the setting, 20% to 80% of all prescriptions are written off-label, and the use of naloxone intranasally is a well-established practice (O’Reilly and Dalal, 2003; Kerr et al., 2009; Wittich et al., 2012). A recent review of relevant law discovered no instances in which a prescriber or dispenser was sued for prescribing or providing naloxone for community use (Davis et al., 2015a). As with any medication, both prescriber and pharmacist should ensure that the patient understands the indications of the medication, possible side effects, and how to administer it in the event of an overdose.

As legislators have realized the need to increase naloxone access to laypersons, the majority of states have implemented laws and regulations to expand opportunities for naloxone prescription and distribution. Additionally, a number of states have passed laws that limit civil and criminal liability for prescribers, dispensers, and administrators, and also “Good Samaritans” who call for help in an overdose emergency, and the overdose victim (Davis et al., 2013; Davis and Carr, 2015).

**Third Party Prescribing**

In recognition of the fact that the person who is at risk of overdose is often not the person that the clinician encounters (ie, often a friend or family member expresses concern to the prescriber about another person at risk), a number of state legislatures have taken action to permit prescribers to prescribe naloxone to people with whom they do not have a prescriber–patient relationship. This is termed “third party prescribing.” In a state that allows for third party prescribing, the legal risk in doing so is no different than that if the prescriber were prescribing directly to the person at risk. Typically, the actual prescription will be written in the name of the person who has directly contacted the prescriber. As of September 2015, 37 states have passed laws permitting third party prescribing of naloxone. The question of whose insurance gets billed for third party prescriptions is an unresolved issue and policies currently differ from place to place.

**Enhanced pharmacy access**

Some pharmacists practicing in federal agencies such as the Indian Health Service and Veterans Administration have prescribing authority, and several states have recently passed laws that permit some pharmacists to prescribe naloxone (U.S. Department of Health and Human Services, 1996; Clause et al., 2001; Davis and Carr, 2015). Where the pharmacist is the prescriber, he or she is generally bound by the same requirements that apply to physicians and other prescribers.

A majority of states have passed laws that permit prescribers and pharmacists to establish CPAs or standing or protocol orders for naloxone. In these states, a pharmacist can dispense naloxone to any individual who meets criteria specified in the agreement or order. Rules and requirements are state-specific, though all states require a written agreement between prescriber and the pharmacy or pharmacist that sets out the terms. As of September 2015, 27 states permit pharmacy standing orders and 12 also permit naloxone to be distributed by laypersons acting under the authority of a prescriber at locations such as community-based organizations and drug treatment centers (Davis et al., 2015b; Wheeler et al., 2015). In many states, standing orders are also used to authorize nonmedical first responders such as firefighters and police officers to possess and administer naloxone (Davis et al., 2014b, 2015a).

**Immunity for Prescribers and Dispensers**

Fear of legal consequences may still discourage some medical professionals from issuing naloxone prescriptions (Beletsky et al., 2007). To address this concern, 32 states have changed their laws to provide full or partial civil immunity to medical professionals who prescribe naloxone as permitted by law, whereas 30 provide such immunity to dispensers and 36 to the person who administers the medication in the event of an overdose. Most of these laws require that the medical professional not act negligently or recklessly in prescribing or dispensing. Because of these laws, prescribing or dispensing naloxone entails less risk in most states than prescribing or dispensing other medications.

**Good Samaritan Laws**

Many people who use illicit drugs or medications other than prescribed may be wary of calling 911 in an overdose for fear of criminal sanctions. Overdose Good Samaritan laws, sometimes known as medical amnesty laws, are intended to encourage bystanders to call for help by providing limited criminal immunity to the person that makes the call, and also to the victim. This immunity is typically limited to relatively minor crimes, although in some states it extends to violations of probation or parole. For prescribers and pharmacists, it is important to let patients prescribed naloxone know of these laws, and reinforce the importance of not only administering naloxone, but also calling emergency medical response (Tobin et al., 2005; Lagu et al., 2006; Pollini et al., 2006).

State-specific naloxone laws can be found at the Public Health Law Research Program’s Law Atlas (www.lawatlas.org).

**CONCLUSIONS**

Prescribers and pharmacists should acknowledge and embrace their role in helping patients to prevent and respond to opioid overdoses. Clinical and legal environments have become more conducive to providing overdose prevention education and naloxone rescue kits. Engaging prescribers and pharmacists is crucial to addressing the overdose epidemic.

**ACKNOWLEDGMENTS**

The Web site www.prescribetoprevent.org is a free online resource to help health care providers educate their patients to reduce overdose risk and provide naloxone rescue kits to patients. We would like to thank the contributors to the Web site.
REFERENCES

Aboud, R. Pharmacy Practice and the Law, 6th ed. Jones & Bartlett; 2010:223. American Medical Association. It's about saving lives: increasing access to naloxone. Available at: http://www.ama-assn.org/ama/ama-wire/post/fs-saving-lives-increasing-access-naloxone. Published June 29, 2015. Accessed July 12, 2015.

American Pharmacists’ Association. APhA Policy: controlled substances and other medications with the potential for abuse and use of opioid reversal agents. Available at: http://www.pharmacist.com/policy/controlled-substances-and-other-medications-potential-abuse-and-use-opioid-reversal-agents-2. Published 2014. Accessed July 12, 2015.

American Society of Addiction Medicine. Public policy statement on the use of naloxone for the prevention of drug overdose deaths. Chevy Chase, MD. Available at: http://www.asam.org/docs/default-source/publicly-policy-statements/naloxone-rev-8-14.pdf. Revised 2014. Accessed July 12, 2015.

Baca CT, Grant KJ. What heroin users tell us about overdose. J Addict Dis 2007;26:63–68.

Beletsky L, Ruthazer R, Macalino GE, et al. Physicians’ knowledge of and willingness to prescribe naloxone to reverse accidental opioid overdose: challenges and opportunities. J Urban Health 2007;84:126–136.

Beletsky L. The benefits and potential drawbacks in the approval of EVZIO for lai reversal of opioid overdose. Am J Prev Med 2015;48:357–359.

Bell J, Matick R, Hay A, et al. Methadone maintenance and drug-related death. J Subst Abuse Treat 1997;9:15–25.

Bennett AS, Bell A, Torneli L, et al. Characteristics of an overdose prevention, response, and naloxone distribution program in Pittsburgh and Allegheny County, Pennsylvania. J Urban Health 2011;88:1020–1030.

Beuger M, Tommasello A, Schwartz R, et al. Clonidine use and abuse among methadone program applicants and patients. J Subst Abuse Treat 1998;15:589–593.

Bukten A, Skurtveit S, Gossop M, et al. Engagement with opioid maintenance treatment and reductions in crime: a longitudinal national cohort study. Addiction 2012;107:393–399.

Burris S, Beletsky L, Castagna C, et al. Stopping an invisible epidemic: legal issues in the provision of naloxone to prevent opioid overdose. Drexel Law Rev 2009;1:273–339.

Caccioppo JT, Hughts ME, Waite LJ, et al. Loneliness as a specific risk factor for depressive symptoms: cross-sectional and longitudinal analyses. Psychol Aging 2006;21:140–151.

Chamberlain JM, Klein BL. A comprehensive review of naloxone for the emergency physician. Am J Emerg Med 1994;12:650–660.

Chen LH, Hedegaard H, Warner M. Drug-poisoning deaths involving opioid analgesics: United States, 1999–2011. NCHS Data Brief 2014;1–8.

Clark AK, Wilder CM, Winstanley EL. A systematic review of community opioid overdose prevention and naloxone distribution programs. J Addict Med 2014;8:153–163.

Clauses S, Fudin J, Mergen A, et al. Prescribing privileges among pharmacists in veterans affairs medical centers. Am J Health Syst Pharm 2001;58:1143–1145.

Clausen T, Waal H, Thoresen M, et al. Mortality among opiate users: opioid maintenance therapy, age and causes of death. Addiction 2009;104:1356–1362.

Coffin PO, Sullivan SD. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. Ann Intern Med 2013;158:1–9.

Dart RC, Surratt HL, Cicero JF, et al. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med 2015;372:241–248.

Dasgupta N, Creppage K, Austin A, et al. Observed transition from opioid analgesic deaths toward heroin. Ann Intern Med 2015a;105:1530–1537.

Davis CS, Carr D, Southwell JK, et al. Engaging law enforcement in overdose reversal initiatives: authorization and liability for naloxone administration. Am J Public Health 2015b;105:1530–1537.

Davis CS, Walley AY, Bridger CM. Lessons learned from the expansion of naloxone access in Massachusetts and North Carolina. J Law Med Ethics 2013;41(Suppl 1):33–36.

Davis CS, Pierce M, Dasgupta N. Evolution and convergence of state laws governing controlled substance prescription monitoring programs, 1998–2011. Am J Public Health 2014a;104:1389–1395.

Davis CS, Southwell JK, Niehaus VR, et al. Emergency medical services naloxone access: a national systematic legal review. Acad Emerg Med 2014b;21:1173–1177.

Doe-Simkins M, Walley AY, Epstein A, et al. Saved by the nose: bystander-administered intranasal naloxone hydrochloride for opioid overdose. Am J Public Health 2009;99:788–791.

Doe-Simkins M, Quinn E, Xuan Z, et al. Overdose rescues by trained and untrained participants and change in opioid use among substance-using participants in overdose education and naloxone distribution programs: a retrospective cohort study. BMC Public Health 2014;14:297.

Dolan KA, Shearer J, White B, Zhou J, et al. Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. Addiction 2005;100:820–828.

Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med 2010;152:85–92.

Enteen L, Bauer J, McLean R, et al. Overdose prevention and naloxone prescription for opioid users in San Francisco. J Urban Health 2010;87:931–941.

Ezio. Kaléo Cares Patient Assistance Program. Available at: http://ezioxo.com/hcp/patient-savings/kaleo-cares-patient-assistance.php. Accessed July 9, 2015.

Fujemiroukon-Odashiyi O, Sinha C, Tutt Y, et al. Pregnancy outcome in women who use opiates. Eur J Obstet Gynecol Reprod Biol 2006;126:170–175.

Gray JA, Hagemeier NE. Prescription drug abuse and DEA-sanctioned drug take-back events: characteristics and outcomes in rural Appalachia. Arch Intern Med 2012;172:1186–1187.

Green TC, Heimer R, Grau LE. Distinguishing signs of opioid overdose and indication for naloxone: an evaluation of six overdose training and naloxone distribution programs in the United States. Addiction 2008;103:979–989.

Green TC, Bowman S, Davis C, et al. Discrepancies in addressing overdose prevention through prescription monitoring programs. Drug Alcohol Depend 2015a;153:355–358.

Green TC, Dauria EF, Bratberg J, et al. Orienting patients to greater opioid safety: models of community pharmacy-based naloxone. Harm Reduct J 2013b;12:25.

Innocenzo TJ, Carroll NV, Read EL, et al. The economic burden of opioid-related poisoning in the United States. Pain Med 2013;14:1534–1547.

International Medications Systems Limited: 2015. Naloxone hydrochloride [package insert]. El Monte, CA.

Junti, Kennedy WK, Lopez G. Benzodiazepines: a major component in unintentional prescription drug overdoses with opioid analogues. J Pharm Pract 2014;27:5–16.

Johnson RE, Jones HE, Jasinski DR, et al. Buprenorphine treatment of pregnant opioid-dependent women: maternal and neonatal outcomes. Drug Alcohol Depend 2001;63:97–103.

Jones CM. Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers: United States, 2002–2004 and 2008–2010. Drug Alcohol Depend 2013;132:95–100.

Jones CM, McAninch JK. Emergency department visits and overdose deaths from combined use of opioids and benzodiazepines. Am J Prev Med 2015;40:749–757(15):00163-4.

Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA 2013;309:657–659.

Jones CM, Paulozzi LJ, Mack KA. Alcohol involvement in opioid pain reliever and benzodiazepine drug abuse-related emergency department visits and drug-related deaths. MMWR Mortal Wkly Rep 2014;63:881–885.

Kerr D, Kelly AM, Dietze P, et al. Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose. Addiction 2009;104:2067–2074.

Kinner SA, Milloy M-J, Wood E, et al. Incidence and risk factors for non-fatal overdose among a cohort of recently incarcerated illicit drug users. Addict Behav 2012;37:691–696.

Krupitsky E, Nunes EV, Ling W, et al. Injectable extended-release naloxone for opioid dependence: a double-blind, placebo-controlled, multicenter randomised trial. Lancet 2011;377:1506–1513.

Limb, C. J Addict Med ● Volume 10, Number 5, September/October 2016

306

© 2016 American Society of Addiction Medicine

Copyright © 2016 American Society of Addiction Medicine. Unauthorized reproduction of this article is prohibited.
Seal KH, Thawley R, Gee L, et al. Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study. *J Urban Health* 2005;82:303–311.

Shapiro BJ, Lynch KL, Tochinda T, et al. Promethazine misuse among methadone maintenance patients and community-based injection drug users. *J Addict Med* 2013;7:96–101.

Smith RV, Lofwall MR, Havens JR. Abuse and diversion of gabapentin among nonmedical prescription opioid users in Appalachian Kentucky. *Am J Psychiatry* 2015;172:487–488.

Soyka M, Trader A, Klotsche J, et al. Criminal behavior in opioid-dependent patients before and during maintenance therapy: 6-year follow-up of a nationally representative cohort sample. *J Forensic Sci* 2012;57:1524–1528.

Sporer KA, Kral AH. Prescription naloxone: a novel approach to heroin overdose prevention. *Ann Emerg Med* 2007;49:172–177.

Strang J, McCambridge J, Best D, et al. Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study. *BMJ* 2003;326:950–956.

Substance Abuse and Mental Health Services Administration. Results from the 2010 Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: Center for Behavioral Health Statistics and Quality. Available at: http://www.samhsa.gov/data/sites/default/files/NSDUHResults/NSDUHRe- sults-2010.pdf. Published 2011. Accessed June 22, 2015.

Substance Abuse and Mental Health Services Administration. “Opioid Overdose Prevention Toolkit.” Rockville, MD. Available at: http://store.samhsa.gov/shin/content/SMA14-4742/Overdose_Toolkit.pdf. Revised Accession. 2014. Published Accession July 12, 2015.

Tobin KE, Davey MA, Latkin CA. Calling emergency medical services during drug overdose: an examination of individual, social and setting correlates. *Addiction* 2005;100:397–404.

Tobin KE, Sherman SG, Beilenson P, et al. Evaluation of the Staying Alive programme: training injection drug users to properly administer naloxone and save lives. *Int J Drug Policy* 2009;20:131–136.

U.S. Centers for Disease Control and Prevention. Multiple causes of death, 1993–2013 query. Available at: http://wonder.cdc.gov/mcd-scd10.html. Accessed June 22, 2015a.

U.S. Centers for Disease Control and Prevention. Deaths from Prescription Overdose. Available at: http://wonder.cdc.gov/drugoverdose/data/overdose.html. Published April 30, 2015b. Accessed June 7, 2015.

U.S. Centers for Disease Control and Prevention. Increases in Fentanyl Drug Confrontation and Fentanyl-related Overdose Fatalities. Available at: http://emergency.cdc.gov/han/han00384.asp. Published October 26, 2015c. Accessed December 11, 2015.

U.S. Department of Health and Human Services. Special General Memorandum 96-2: Designation of Pharmacists as Primary Care Providers with Prescriptive Authority. Available at: http://www.hhs.gov/hihm/index. cfm?module=dsb_hi_hgm_main&gs=hihm_hgm_9602. Published October 18, 1996. Accessed July 27, 2015.

U.S. Department of Health and Human Services. Opioid Abuse in the U.S. and HHS Actions to Address Opioid-Drug Related Overdoses and Deaths. Available at: http://aspe.hhs.gov/sp/reports/2015/OpioidInitiative/ib_OpioidInitiative.cfm. Published March 26, 2015. Accessed July 10, 2015.

U.S. Drug Enforcement Administration. Final Rule on Disposal of Controlled Substances. Available at: https://www.federalregister.gov/articles/2014/09/09/2014-20026/disposal-of-controlled-substances. Published September 9, 2014. Accessed June 22, 2015.

U.S. Drug Enforcement Administration. National Take-Back Initiative. Available at: http://www.deadvension.usdoj.gov/drug-disposal/takeback/. Published 2015. Accessed June 22, 2015.

U.S. Food and Drug Administration. FDA Commissioner Margaret A. Hamburg Statement on Prescription Opioid Abuse. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm391590.htm. Published April 3, 2014. Accessed July 6, 2015.

U.S. Food and Drug Administration. FDA moves quickly to approve easy-to-use nasal spray to treat opioid overdose. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm435055.htm. Published November 18, 2015. Accessed December 12, 2015.

U.S. Food and Drug Administration. FDA’s Efforts to Address the Misuse and Abuse of Opioids. Available at: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm337852.htm. Published February 6, 2013. Accessed August 13, 2015.
United Nations Office on Drugs and Crime. World Drug Report 2014. Vienna, Austria. Available at: http://www.unodc.org/documents/wdr2014/World_-Drug_Report_2014_web.pdf. Published 2014. Accessed July 12, 2015.

Wagner KD, Valente TW, Casanova M, et al. Evaluation of an overdose prevention and response training programme for injection drug users in the Skid Row area of Los Angeles, CA. Intl J Drug Policy 2010;21:186–193.

Walley AY, Doe-Simkins M, Quinn E, et al. Opioid overdose prevention with intranasal naloxone among people who take methadone. J Subst Abuse Treat 2013a;44:241–247.

Walley AY, Xuan Z, Hackman HH, et al. Opioid overdose rates and implementation of overdose education and naloxone distribution in Massachusetts: interrupted time series analysis. BMJ 2013b;346:e174.

Wheeler E, Davidson PJ, Jones TS, et al. Community-based opioid overdose prevention programs providing naloxone: United States, 2010. MMWR Morb Mortal Wkly Rep 2012;61:101–105.

Wheeler E, Jones TS, Gilbert M, et al. Opioid overdose prevention programs providing naloxone to laypersons. MMWR Morb Mortal Wkly Rep 2015;64:631–635.

White JM, Irvine RJ. Mechanism of fatal opioid overdose. Addiction 1999;94:961–972.

Wittich CM, Burkle CM, Lanier WL. Ten common questions (and their answers) about off-label drug use. Mayo Clin Proc 2012;87:982–990.

Wolff K. Characterization of methadone overdose: clinical considerations and the scientific evidence. Drug Monit 2002;24:457–470.

World Health Organization. Community management of opioid overdose. Geneva, Switzerland. Available at: http://apps.who.int/iris/bitstream/10665/137462/1/9789241548816_eng.pdf?ua=1&ua=1. Published 2014. Accessed July 12, 2015.

Zedler B, Xie L, Wang L, et al. Risk factors for serious prescription opioid-related toxicity or overdose among Veterans Health Administration patients. Pain Med 2014;15:1911–1929.